ZymoGenetics (ZGEN) Announces Merck Serono to Discontinue Study in Lupus Nephritis in Ongiong Phase II/III Trials
Tweet Send to a Friend
In a Form 8-K, ZymoGenetics (Nasdaq: ZGEN) announced that on October 27, Merck Serono announced that it was discontinuing the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE